1/13
04:06 am
pcvx
Vaxcyte (NASDAQ:PCVX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Vaxcyte (NASDAQ:PCVX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/7
07:08 am
pcvx
Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
Low
Report
Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
1/3
10:46 am
pcvx
Vaxcyte's Chief Technical Ops Officer Sells Shares [Yahoo! Finance]
Low
Report
Vaxcyte's Chief Technical Ops Officer Sells Shares [Yahoo! Finance]
12/23
03:34 pm
pcvx
What Makes Vaxcyte (PCVX) So Attractive [Yahoo! Finance]
Low
Report
What Makes Vaxcyte (PCVX) So Attractive [Yahoo! Finance]
12/14
03:11 pm
pcvx
How Vaxcyte's Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors [Yahoo! Finance]
Low
Report
How Vaxcyte's Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors [Yahoo! Finance]
12/14
02:43 pm
pcvx
Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price [Yahoo! Finance]
Low
Report
Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price [Yahoo! Finance]
12/11
11:30 am
pcvx
Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension [Yahoo! Finance]
Low
Report
Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension [Yahoo! Finance]
12/8
07:00 am
pcvx
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Low
Report
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
11/21
07:53 am
pcvx
Vaxcyte (PCVX): Evaluating Valuation After a 48% Three-Month Share Price Rebound [Yahoo! Finance]
Low
Report
Vaxcyte (PCVX): Evaluating Valuation After a 48% Three-Month Share Price Rebound [Yahoo! Finance]
11/19
07:00 am
pcvx
Vaxcyte (NASDAQ:PCVX) was given a new $77.00 price target on by analysts at Leerink Partners.
Medium
Report
Vaxcyte (NASDAQ:PCVX) was given a new $77.00 price target on by analysts at Leerink Partners.
11/14
03:22 am
pcvx
Medicxi Announces €500 Million Fund V [Yahoo! Finance]
Medium
Report
Medicxi Announces €500 Million Fund V [Yahoo! Finance]
11/14
03:06 am
pcvx
Medicxi closes fifth fund to back ‘asset-centric' startups [Yahoo! Finance]
Medium
Report
Medicxi closes fifth fund to back ‘asset-centric' startups [Yahoo! Finance]
11/10
08:03 am
pcvx
Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $85.00 price target on the stock.
Low
Report
Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $85.00 price target on the stock.
11/4
04:05 pm
pcvx
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
Low
Report
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study